

Lixisenatide acetate

Cat. No.: HY-P0119A
CAS No.: 1997361-87-1
Molecular Formula: C₂₁₅H₃₄₇N₆₁O₆₅S₆C₂H₄O₂
Molecular Weight: 5218.79
Sequence Shortening: HGEFTTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPSKKKKKK-NH₂
Target: GCGR
Pathway: GPCR/G Protein
Storage: Sealed storage, away from moisture
 Powder -80°C 2 years
 -20°C 1 year

HGEFTTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPSKKKKKK-NH₂



* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

SOLVENT & SOLUBILITY

In Vitro	H ₂ O : 50 mg/mL (9.58 mM); Need ultrasonic					
	Preparing Stock Solutions	Solvent Concentration	Mass	1 mg	5 mg	10 mg
			1 mM	0.1916 mL	0.9581 mL	1.9162 mL
		5 mM	0.0383 mL	0.1916 mL	0.3832 mL	
		10 mM	---	---	---	
Please refer to the solubility information to select the appropriate solvent.						
In Vivo	1. Add each solvent one by one: PBS Solubility: 100 mg/mL (19.16 mM); Clear solution; Need ultrasonic					

BIOLOGICAL ACTIVITY

Description	Lixisenatide acetate is a glucagon-like peptide-1 (GLP-1) receptor agonist that can be used in the treatment of type 2 diabetes mellitus (T2DM).
IC ₅₀ & Target	GLP-1 receptor ^{[1][2]} .

CUSTOMER VALIDATION

- J Mol Neurosci. 2020 Feb 10.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Ahrén B et al. Postprandial Glucagon Reductions Correlate to Reductions in Postprandial Glucose and Glycated Hemoglobin with Lixisenatide Treatment in Type 2 Diabetes Mellitus: A Post Hoc Analysis. *Diabetes Ther.* 2016 Jun 18.

[2]. Lorenz M, et al. Effects of lixisenatide once daily on gastric emptying in type 2 diabetes--relationship to postprandial glycemia. *Regul Pept.* 2013 Aug 10;185:1-8.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA